Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis.

CONCLUSION: E6005 ointment exhibited acceptable safety and tolerability. Topical application of E6005 ointment resulted in very low systemic exposure to E6005 in healthy volunteers and in patients with AD. PMID: 26581111 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26581111?dopt=Abstract

Source: Journal of Dermatological Treatment - February 16, 2016 Category: Dermatology Tags: J Dermatolog Treat Source Type: research